Injectable nanoparticles deliver cancer therapy in mice

NIH | APRIL 9, 2016

Many drugs for treating cancer work by slowing or stopping the growth of cancerous cells. However, there are numerous barriers that can hinder a drug’s ability to work successfully. A drug needs to reach and get inside cancerous cells. The drug must also avoid damaging healthy cells to prevent side effects.

Accumulation of pDox nanoparticles, highlighted by green arrow. Image credit: Xu et al., Nature Biotechnology

A team at Houston Methodist Research Institute has been working to overcome the many hurdles to successful cancer treatment by harnessing nanotechnology to deliver drugs directly into cancerous cells.

The scientists turned to doxorubicin (dox), a drug used to treat many cancer types. They attached dox to string-like molecules, known as poly(L-glutamic acid), through a pH-sensitive link. This formed a drug complex called pDox. The team made disk-shaped, micrometer-sized silicon particles to serve as a carrier for the pDox. The pDox was loaded into the particles through nanometer-sized pores.

When the researchers injected pDox-containing silicon particles intravenously into mice with cancerous tumors, the particles traveled through the blood stream and accumulated at the site of tumors, where blood vessels are leakier. The silicon, which was designed to degrade, released pDox molecules at the tumor site. These molecules spontaneously formed nanoparticles, which were then taken up by tumor cells.

Once inside cancerous cells, the pDox was transported to the area around the nucleus through vesicular transport. Due to the acidic environment near the nucleus, the dox was cleaved from its attachment to the poly(L-glutamic acid). This resulted in a high concentration of dox within the nuclei of the cancerous cells.

The team tested the therapy in several mouse cancer models. Mice treated with the pDox-containing particles had much smaller and fewer tumors. They also had a longer survival time than mice given a saline control. The group found that 40-50% of cancer-bearing mice given the treatment showed no signs of metastatic tumors 8 months later.

YOU MAY ALSO LIKE

A biological mechanism for schizophrenia

Scientists identified the mechanism behind genetic variations that were linked to schizophrenia in previous genomic studies.

DNA damage caused by cancer treatment reversed by ZATT protein

An international team led by scientists at the National Institutes of Health is the first to discover a new way that cells fix an important and dangerous type of DNA damage known as a DNA-protein crosslink (DPC).

Heart Disease Severity May Depend on Nitric Oxide Levels

The most common heart medications may get an assist from nitric oxide circulating in the body, according to a new study.

Infants, Toddlers at More Risk from Exposure to Second-Hand Smoke than Thought

A new study finds that infants and toddlers in low-income communities may be even more at risk from second -hand smoke exposure than has been thought.

Reproductive Problems Reported In Lab Mice after BPA Replacements in Plastics

Researchers found that the array of alternative bisphenols now used to replace BPA in BPA-free bottles, cups, cages, and other items appear to be causing a sudden increase in chromosomally abnormal eggs in the lab mice.

Antibiotic Combinations May Combat MRSA Infections

A trio of antibiotics that had become powerless against MRSA decades ago proved effective in infected mice when used together.